anaemia is never due to auto-anti-A or autoanti-B. It seems likely that this is due to the corresponding antigens being powerful and ubiquitous. In contrast AIHA does result from the development of antibodies against Rh antigens which appear to be weaker antigens than A and B and are confined to the red cells. Moreover, when auto-Rh-antibodies are developed, these are more often than not found to be directed against relatively weak Rh antigens such as e or c, which rarely provoke iso-antibody formation. In contrast, auto-antibodies are relatively infrequently developed against the D antigen which, judged by the frequency of isoanti-D, is the strongest of the Rh antigens.
The next point to make in relation to the clonal hypothesis is that there is a striking frequency of AIHA in association with malignant disease of the lymphoreticular tissue, i.e., in chronic lymphocytic leukaemia, other malignant lymphomas and reticulosarcoma. Here are disorders in which clones of abnormal cells are certainly present and it is tempting to believe that these patients have an unusual proneness to produce such clones. However, it is not clear in cases of lymphoma associated with AIHA whether or not the anti-red-cell antibodies are being formed by the malignant lymphoid cells, or from a separately existing clone of nonmalignant cells.
Another association in favour of the hypothesis that abnormal antibodies are produced by self-perpetuating clones of antibody-forming cells is the long duration of the cold-hwemagglutinin disease and the occasional appearance, sometimes after years of a slowly progressive but apparently benign illness, ofa terminal lymphoma, the consequence presumably of the emergence of a new overtly malignant clone of cells.
To summarize, the xetiology of AIHA is clearly complex. Five points can be made:
(1) There is no single cause.
(2) There is probably an individual tendency to develop, or an unusual ability to form, autoantibodies, which may be genetic in origin. That genetic factors can be important is illustrated by the regular occurrence of AIHA in the hybrid New Zealand mice (Bielschowsky et al. 1959) . A small but probably significant number of familial occurrences have also been reported in man (Fialkow et al. 1964) .
(3) On the background of a probably genetic tendency to form auto-antibodies a number of causes (methyldopa seems to be one) lead to the development or persistence of clones of cells which form antibodies against certain red-cell antigens. The antibodies produced show striking individual characteristics. (4) Auto-antibodies against red cells are found particularly frequently in association with malignant lymphoproliferative diseases, i.e., in people who clearly are forming clones of cells which functionally are related to antibody-forming cells.
(5) A complete understanding of the AIHAs will not be arrived at until the normal mechanism of tolerance to self antigens is fully understood. 
Drug-induced Immune Hemolysis
It is well recognized that drugs may cause nwmelysis by a direct chemical effect on erythrocytes, especially those which are already biochemically abnormal. However, this communication will deal briefly with those instances of drug-induced haemolysis brought about by immune mechanisms, that is where a drug stimulates the formation of antibody which directly or indirectly leads to an increased rate of red cell destruction. These events are usually accompanied by a positive direct Coombs test (DCT). It is probable that at least three alternative mechanisms are involved. The first is known as the 'innocent bystander' reaction, accompanied by a positive direct Coombs test (DCT) of the 'complement' or 'non-gamma' type. The second is the 'hapten' or penicillin reaction, and this is associated with a positive DCT of the y G (IgG) type. The third is the 'methyldopa' reaction, also associated with a positive DCT of the IgG type. Table 1 ). For other drugs and bibliography see Dacie (1967) . Following the investigations of Shulman (1964) it appears that the reaction is brought about in the following manner. Administration of the drug stimulates formation of antibodies, some of which are specific for the drug itself. In the blood stream, antibody combines with antigen (the drug) to form a complex which becomes loosely attached to the surface of RBC. The presence of this complex binds complement to the RBC, which can lead to hiemolysis. It is possible that complexes can then be liberated from the RBC and be free to attach to other cells. As the antibody-antigen complex is only loosely attached, no immunoglobulin is detected by the DCT, only complement fractions. Serum from affected patients will only produce a positive indirect Coombs test if drug and complement are present in the test system. It should be noted that the total number of reported cases of this type of hemolysis is small.
Mechanism II. The Hapten (Penicillin) Reaction This reaction has only been reported following the administration of penicillin in massive doses (Beardwell 1964 , Petz & Fudenberg 1966 , Swanson et al. 1966 . In these cases IgG antibodies (not the more usual IgM antibodies) are formed against penicillin or a metabolite. Part of the penicillin molecule also binds very firmly to the red cell membrane. Thus, in the blood stream a stable complex of RBC-penicillin-antibody is formed. The presence of sufficient IgG molecules on the RBC surface can cause hemolysis. The DCT is always positive and is of the IgG type. Patients' serum will only react with normal RBC if these have been previously coated with penicillin. As with drugs of the previous group, very few cases have been reported. Cephalothin has also been reported to cause a positive DCT, together with anemia, but the significance of these findings is far from clear (Molthan et al. 1967 ).
Mechanism III. The Methyldopa Reaction This is characterized by the occurrence of a positive DCT (IgG type) in patients taking the drug, and occasionally by a haemolytic anmmia, of any grade of severity, which is indistinguishable clinically and serologically from idiopathic autoimmune hemolytic anmmia (AIHA), warm antibody type (Carstairs, Worlledge, Dollery & Breckenridge 1966 , Carstairs, Breckenridge, Dollery & Worlledge 1966 ). This is a very different situation from the other two. The mechanism is not understood. The reaction occurs more frequently, and the antibodies do not appear to be directed against the drug.
The incidence of a positive DCT in patients receiving methyldopa is dose dependent. The figures from various laboratories vary. Carstairs, Breckenridge, Dollery & Worlledge (1966) reported an incidence of approximately 10 % in patients receiving 1 g or less per day, 20% in patients receiving 1-25-2 g per day and 36% in those receiving more than 2 g per day. There was an overall incidence of 20 % in their series of 202 patients. In another series from the same laboratory Breckenridge et al. (1967) reported that 46% of patients receiving more than 2 g per day had a positive DCT. Lo Buglio & Jandl (1967) reported an overall incidence of 10-6%, but did not give details of dosage. The DCT usually becomes positive about five to nine months after starting therapy.
Overt hiemolysis is very much rarer. Although it is difficult to obtain precise data, it probably occurs in 01 % or less of those at risk. The angemia responds well to withdrawal of the drug and/or prednisone therapy.
Mechanism: Methyldopa is an amino acid (3, 4, hydroxy-a-methyl-phenylalanine) widely used in the treatment of hypertension. It can stimulate the production of antibodies which react well with any normal RBC, poorly with -D-cells and not at all with fresh Rhnuil cells (cells lacking all Rhesus antigens). So far it has not been possible to demonstrate any reaction between antibody and the drug, or between antibody and drug analogues or metabolites (Lo Buglio & Jandl 1967 ). If the antibody is directed primarily against the Rh antigens and is not cross-reacting with them, then it seems likely that the reaction is mediated either through changes in the RBC themselves, or the antibody forming tissue, or the plasma in which the RBC circulate.
(1) Changes in the RBC: As the DCT does not become positive for some months, it is possible that methyldopa is incorporated into the developing erythrocyte and in so doing alters the Rhesus antigens. This change might not be recognized until the cell is destroyed by the reticulo-endothelial system four months later. Allowing some weeks for the level of antibody to reach recognizable levels, then the predicted time for the DCT to become positive neatly matches the observed time. The alteration of the Rhesus antigens would have to be sufficient to cause autoantigenicity yet subtle enough to allow the antibodies so formed to react with normal antigens. But it has been noted that the DCT becomes negative quite rapidly on withdrawal of the drug. Breckenridge et al. (1967) reported that of 23 patients taken off methyldopa treatment for six months, 7 were negative in three months, and 12 negative by six months. One might expect that the cohorts of RBC formed prior to termination of therapy would continue to stimulate the reticulo-endothelial for approximately four months. Even after making allowances for decreased antibody production, for the natural decay of preformed antibody, and possible variations in laboratory technique it is surprising that many patients revert so quickly to normal. Some of the objections to this theory might be countered if the methyldopa altered mature cells, but this assumption introduces further difficulties.
(2) Changes in antibody-forming tissues: This hypothesis implies that the drug acts on the antibody-forming tissue. Breckenridge et al. (1967) have suggested that the handling of cell fragments may become altered by methyldopa, causing them to become antigenic.
Alternatively methyldopa could interfere with the control of antibody production. How the body recognizes 'self' antigens is still a matter for conjecture. If the body were to possess the capability of forming antibodies to 'self' antigens, and this potential were held in cistrons, either 'inaccessible' (blocked by histones or other substances) or 'inactive' (blocked by repressor substances), then presumably this mechanism could fail. Those 'self' antigens of limited distribution (like the Rh antigens which figure so prominently in diseases of the reticulo-endothelial system) might be particularly susceptible. Methyl-dopa could then operate by modifying the structure or function of a particular substance (e.g. histone) so allowing forbidden cistrons to become active. The time taken to produce antibody would depend on the half-life of the repressing agent, thus antibody production might begin shortly after the initiation of therapy, but detectable antibody levels could take some months to accumulate. Similarly, cessation of therapy could lead to a rapid 'switching-off' of antibody production.
There is a slight possibility that methyldopa could be incorporated into an antibody originally designed for another purpose, and transform it into an anti-Rh antibody.
(3) Alteration ofplasma constituents: Modification of pre-existing proteins would be required to support this hypothesis, but it is difficult to see how this could come about.
Finally, it might be appropriate to mention that a fair proportion by weight of a methyldopa tablet consists of substances other than the drug, which are necessary for stabilizing methyldopa and for providing the qualities required for easy manufacture, and maintenance of the tablet's appearance and integrity. Many of the ingredients are widely used in other tablets, but few preparations are taken in such numbers over a long period of time. It may not be justifiable to assume that it is the ingredient present in largest amount that is necessarily the cause of the reaction. Summary A variety of drugs can cause hemolysis by immune mechanisms. There are at the moment three separate mechanisms recognized. These are either briefly described or made the subject of free speculation.
